ppOrganisation/Company Fundació Hospital Universitari Vall d'Hebron- Institut de recerca Department Research Department Research Field Biological sciences » Biology Researcher Profile Recognised Researcher (R2) Positions Postdoc Positions Application Deadline 31 Jul 2026 - 23:59 (Europe/Andorra) Country Spain Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme? Other EU programme Is the Job related to staff position within a Research Infrastructure? No /ph3Offer Description /h3pbDevelopment of an in vitro diagnostic triage test for patients at risk of endometrial hyperplasia and endometrial cancer based on protein biomarkers in cervical fluids /b /ppVHIR is seeking an outstanding and highly motivated postdoctoral researcher to apply for a Marie Sklodowska-Curie Postdoctoral Fellowship and join the Biomedical Gynaecology Research Group. /ppThe Marie Skłodowska-Curie Postdoctoral Fellowships (MSCA-PF) are part of the Horizon Europe programme and support postdoctoral researchers in developing an original research and innovation project through international mobility. /ppThe programme aims to strengthen researchers’ careers through excellent science, international collaboration and interdisciplinary experience, while fostering integration in both academic and non‑academic environments. The MSCA-PF call is highly competitive and represents an excellent opportunity to attract international talent and support researchers in consolidating their scientific careers through an ambitious mobility‑based fellowship. /ppThe 2026 call closes on 09/09/2026 (17:00 Brussels time). For candidates applying to a European Postdoctoral Fellowship, the fellowship duration is from b12 to 24 months /b. /ppEndometrial cancer (EC) is the fourth most common cancer in women, and its incidence is increasing. Despite the importance of early diagnosis for patient survival, there is no accurate and non‑invasive strategy for early triage or screening of EC. Diagnosis relies on imaging and invasive biopsies, affecting more than 35M women presenting symptoms -86% postmenopausal and 14% premenopausal- and patients with hereditary risk -Lynch Syndrome- who have annual surveillance. Only 10% of those will have EC. /ppbObjective /b /ppThis project builds on our previous projects, and aims to badvance the development of a non‑invasive triage test based on protein biomarkers in cervical fluids for the accurate detection of atypical endometrial hyperplasia (AEH) and EC across high‑risk populations. /b We will advance the development, preanalytical and analytical validation of the test using the recently developed key reagents, and assess its performance in symptomatic pre- and postmenopausal women prior and after imaging techniques, and Lynch Syndrome carriers. In parallel, we will investigate the proteomic landscape of EC progression using a transgenic mouse model, and cervical fluids from AEH patients, to elucidate tumour progression mechanisms and AEH biomarkers, with the ultimate goal to advance our triage test for EC prevention. This project is expected to transform EC diagnosis, improving patient care, quality of life, EC survival, and healthcare efficiency.



/ppbOur Group /b /ppThe bGroup of Biomedical Research in Gynaecology (GineLab) /b, integrated into the Vall d’Hebron Research Institute (VHIR), is a consolidated, multidisciplinary core consisting of 37 professionals who operate under a "two-way translational research" philosophy: from the patient to the laboratory and back to the clinic. The group is co‑directed by Dr. Antonio Gil‑Moreno, who leads the clinical strategy, and Dr. Eva Colás, who is responsible for translational research and innovation. /ppTheir activity is centred on resolving clinical needs in women’s health through two main pillars: early non‑invasive diagnosis and precision oncology. The research is structured into three primary vertical work lines: /pullibEndometrial Cancer: /b This research line is a pioneer in molecular diagnosis using gynaecological fluids (such as cervical fluid), employing proteomics to develop non‑invasive triage tests aimed at avoiding unnecessary biopsies. /lilibOvarian Cancer: /b This research line focuses on precision oncology and therapy optimisation. To this end, they utilise the GynePDX platform, a biobank featuring over 174 patient‑derived xenograft (PDX) models and organoids, which is used for preclinical "clinical trials" of targeted therapies. /lilibEndometriosis: /b This research line integrates molecular classification and tissue proteomic characterisation with the development of a non‑invasive diagnostic test based on protein biomarkers in cervical fluids, while simultaneously investigating angiogenic biomarkers to improve recurrence risk prediction. /li /ulpbInnovation and Clinical Translation /b GineLab stands at the forefront of clinical innovation through a robust portfolio of active patents and the creation of its own femtech spin‑off, bMiMARK Diagnostics S.L. /b (founded in 2021). This spin‑off has secured approximately €8M in funding, including a prestigious €2.5M EIC Accelerator grant, to bring non‑invasive in vitro diagnostic (IVD) tests to the general healthcare market. /ppbInternational Leadership and Strategic Collaborations: /b The group holds a prominent position in the international scientific community: /pullibConsortia Coordination: /b GineLab coordinates the European CytoMARK consortium (ERA PerMed), integrating proteomic markers and clinical data across five countries. /lilibAccreditations: /b The clinical headquarters at VHH maintains ESGO Accreditation as a Centre of Excellence for the surgical management of advanced ovarian cancer. /lilibStrategic Alliances: /b The group maintains high‑level collaborations with institutions such as the Broad Institute of MIT and Harvard, the Luxembourg Institute of Health, and numerous European and US universities. /lilibScientific Governance: /b Members hold leadership roles in the European Network for Individualised Treatment of Endometrial Cancer (ENITEC), the European Society of Gynaecological Oncology (ESGO),



and the national Spain‑GOG network. /li /ulpbSocial Impact and Talent Development /b: Beyond technical excellence, the group drives social change through the ENDO‑HIT program, a pioneer citizen‑science initiative that raises endometriosis awareness in schools and empowers women regarding their reproductive health. Furthermore, GineLab is a proven engine for academic development, having supervised 6 PhD theses with honours since 2022 and maintaining a robust internal training program that attracts international talent from across Europe. /ppbMain responsibilities and duties: /b /pulliParticipate in translational research projects to improve endometrial cancer and endometriosis diagnosis through biomarker research. /liliCollaborate with other projects of the group, by promoting fruitful discussions or by helping in experimental work. /liliParticipate in general activities of the group. /liliSupport the principal researcher in managerial activities. /liliApplicants must hold a PhD degree or have successfully defended their thesis before the call deadline (09/09/2026) /liliApplicants must comply with the mobility rule, meaning they must not have resided or carried out their main activity (work/studies) in the host country for more than 12 months during the 36 months prior to the call deadline. /liliFluency in English /liliFirst author in publications /liliPassionate, proactive, willing to learn and committed /li /ulpbExperience and knowledge: /b /ppbRequired: /b /pulliApplicants must have a maximum of b8 years of postdoctoral research experience /b by the call deadline. This means candidates are generally eligible if they obtained their PhD bon or after 10/09/2018 /b (possible extensions may apply, e.g. parental leave or long‑term illness). /liliPrevious experience in a translational research group /liliExperience in mass spectrometry and immunoassay, including experimental work and data analysis /liliPrevious experience with handling of complex human samples /liliEfficient in manuscript drafting /li /ulh3Additional Information /h3pSelection process /ppbDeadline to apply: /b /ppAdditional comments /ppVHIR embraces Equality and Diversity. As reflected in our values we work toward ensuring inclusion and equal opportunity in recruitment, hiring, training, and management for all staff within the organisation, regardless of gender, civil status, family status, sexual orientation, gender identity and expression, religion, age, functional diversity or ethnicity. /ppInformation on Personal Data Protection:br/Data Controller: Fundació Hospital Universitari Vall d’Hebron Institut de Recerca -VHIR-. Purpose: Personnel selection. Legal Basis: Your consent. Data retention period: One year. If you are selected, as long as the employment relationship is in force and legal responsibilities may arise. Data sharing: Does not occur, except for communications necessary to fulfill the purpose and those required by law to public and private bodies. Rights: You can access, rectify, delete, object to, and limit the processing of data, as well as request data portability where applicable, by contacting . DPO: . More information can be found here . Data Protection Authority: APDCAT /p /p #J-18808-Ljbffr

📌 VHIR-MSCA-.009_Postdoctoral Fellowship (Biomedical Gynaecology) (España)
🏢 Fundacio Hospital Universitari Vall d'Hebron- Institut de recerca
📍 España